NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $28.57 -0.36 (-1.24%) (As of 01:32 PM ET) Add Compare Share Share Today's Range$28.57▼$29.0450-Day Range$25.39▼$30.2152-Week Range$16.88▼$31.99Volume876 shsAverage Volume3,273 shsMarket Capitalization$11.43 millionAssets Under Management$11.59 millionDividend Yield0.30%Net Expense Ratio0.79% Stock AnalysisStock AnalysisChartHoldingsRatingsStock AnalysisChartHoldingsRatings Get Virtus LifeSci Biotech Clinical Trials ETF alerts: Email Address About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC)The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.Read More BBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBC ETF News HeadlinesAugust 19, 2024 | benzinga.comFDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | theglobeandmail.comTech ETFs on the Rise After Four Weeks in Deep RedSeptember 16, 2024 | Market JAR (Ad)BREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.July 20, 2024 | lse.co.ukVirtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukVirtus Lifesci Biotech Clinical Trials Etf Share ChatMay 22, 2024 | bbc.comDrama at Trump trial as judge reprimands witness and clears courtSeptember 26, 2023 | bbc.co.ukSkipton hotel boss cleared as death crash trial collapsesJuly 30, 2023 | bbc.co.ukPuberty blockers to be given only in clinical researchSeptember 16, 2024 | Market JAR (Ad)BREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.June 29, 2023 | ft.comBiotech begins human trials of drug designed by artificial intelligenceSee More Headlines Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings122 Fund Statistics Assets Under Management$11.59 million Average Daily Volume$1,794.90 Discount/Premium-0.05% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest2,000 shs Miscellaneous Outstanding Shares400,004Beta1.22 Creation Unit50,000 Creation Fee$500.00 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Ad Market JARBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.Don't miss out. Get the full details on this AI bargain. Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.54%0.51%0.52%Other Expenses0.00%0.33%0.49%0.58%0.54%Total Expense0.79%0.71%0.70%0.73%0.71%Fee Waiver0.00%-0.45%-0.52%-0.68%-0.58%Net Expense0.79%0.61%0.61%0.57%0.59% Virtus LifeSci Biotech Clinical Trials ETF (BBC) Holdings & ExposureTop 10 BBC HoldingsSummit Therapeutics(NASDAQ:SMMT)Holding Weight: 2.30%Bny Mellon Cash Reserve UsdHolding Weight: 1.87%Longboard Pharmaceuticals(NASDAQ:LBPH)Holding Weight: 1.38%Vaxcyte(NASDAQ:PCVX)Holding Weight: 1.26%Viridian Therapeutics(NASDAQ:VRDN)Holding Weight: 1.24%IGM Biosciences(NASDAQ:IGMS)Holding Weight: 1.21%AnaptysBio(NASDAQ:ANAB)Holding Weight: 1.20%Praxis Precision Medicines(NASDAQ:PRAX)Holding Weight: 1.19%Arbutus Biopharma(NASDAQ:ABUS)Holding Weight: 1.18%Nurix Therapeutics(NASDAQ:NRIX)Holding Weight: 1.17%BBC Sector ExposureBBC Industry ExposureFull Holdings Details Similar ETFsJPMorgan Healthcare Leaders ETFNASDAQ:JDOCDirexion Daily Pharmaceutical & Medical Bull 3X SharesNYSEARCA:PILLHarbor Health Care ETFNYSEARCA:MEDIHorizon Kinetics Medical ETFNASDAQ:MEDXProShares UltraShort Nasdaq BiotechnologyNASDAQ:BIS BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $24.45 at the start of the year. Since then, BBC shares have increased by 18.6% and is now trading at $29.00. View the best growth stocks for 2024 here. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Simon Property Group (SPG) and Cisco Systems (CSCO). This page (NYSEARCA:BBC) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.